Unnamed: 0,title,date,stock,sentiment
226805.0,Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets,2020-06-01 16:06:00-04:00,CDXS,positive
226806.0,"HC Wainwright & Co. Reiterates Buy on Codexis, Lowers Price Target to $21",2020-05-11 07:18:00-04:00,CDXS,negative
226807.0,"Codexis Q1 EPS $(0.090) Beats $(0.140) Estimate, Sales $14.700M Beat $13.250M Estimate",2020-05-07 16:46:00-04:00,CDXS,neutral
226808.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,CDXS,negative
226809.0,"Codexis Reports Achieved Wave 2 Milestone Associated With CodeEvolver Platform, License Deal With Novartis",2020-05-06 16:27:00-04:00,CDXS,neutral
226810.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,CDXS,neutral
226811.0,Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders,2020-03-23 07:02:00-04:00,CDXS,positive
226812.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,CDXS,negative
226813.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,CDXS,negative
226814.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,CDXS,neutral
226815.0,86 Stocks Moving In Friday's Mid-Day Session,2020-02-28 12:19:00-05:00,CDXS,negative
226816.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,CDXS,negative
226817.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,CDXS,neutral
226818.0,Codexis Sees FY20 Sales $78M-$82M,2020-02-27 16:23:00-05:00,CDXS,neutral
226819.0,"Codexis Q4 EPS $0.02 Down From $0.03 YoY, Sales $18.7M Miss $21.31M Estimate",2020-02-27 16:23:00-05:00,CDXS,negative
226820.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,CDXS,negative
226821.0,"Codexis Reports Development Deal With Nestle Health Science For Advancement Of Therapeutic Candidate Towards Clinical Studies, Extends Collaboration",2020-01-10 07:04:00-05:00,CDXS,positive
226822.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,CDXS,negative
226823.0,Codexis to License its EvoT4 to Roche,2019-12-23 07:04:00-05:00,CDXS,neutral
226824.0,"Codexis Highlights Publication, With Merck, Of Efficient Enzymatic Cascade Process For Synthesis Of Investigational Anti-HIV Agent, Islatravir",2019-12-05 16:19:00-05:00,CDXS,positive
226825.0,Codexis Reaffirms FY19 Sales $69M-$72M vs $70.5M Estimate,2019-11-05 16:35:00-05:00,CDXS,neutral
226826.0,"Codexis Q3 EPS $0.04, Sales $21.9M Up From $16.946M YoY",2019-11-05 16:35:00-05:00,CDXS,neutral
226827.0,90 Biggest Movers From Yesterday,2019-08-08 05:17:00-04:00,CDXS,neutral
226828.0,"Codexis Q2 EPS $(0.08) Beats $(0.1) Estimate, Sales $12.3M Miss $14.22M Estimate",2019-08-06 16:27:00-04:00,CDXS,negative
226829.0,Casdin Capital Invests $50M In Codexis With $16.40/Share Private Placement,2019-06-20 07:07:00-04:00,CDXS,neutral
226830.0,Codexis Reports License Deal With Novartis To Develop Novel Performance Enzymes For Using In Manufacturing Pharma Products,2019-05-15 09:08:00-04:00,CDXS,positive
226831.0,"Codexis Q1 EPS $(0.09) Beats $(0.1) Estimate, Sales $15.58M Beat $14.63M Estimate",2019-05-06 16:07:00-04:00,CDXS,neutral
226832.0,Codexis Signs Multi-Year Enzyme Supply And Licensing Agreement with Tate & Lyle For The Manufacture Of TASTEVA M Stevia Sweetener,2019-04-30 07:16:00-04:00,CDXS,positive
226833.0,Codexis Sees FY19 Sales $69M-$72M vs $73.84M Est.,2019-02-26 16:14:00-05:00,CDXS,neutral
226834.0,"Codexis Q4 Adj. EPS $0.03 Beats $(0.03) Estimate, Sales $16.07M Miss $16.66M Estimate",2019-02-26 16:12:00-05:00,CDXS,negative
226835.0,Codexis Reports Nestle Health Science Exercised Option For Exclusive Global License For CDX-6114 For Mgmt. Of Phenylketonuria; Option Triggers $3M Milestone Payment,2019-02-14 07:25:00-05:00,CDXS,positive
226836.0,Codexis Announces Enzyme Supply Agreement With KYORIN Pharmaceutical For Overactive Bladder Drug Sold In Japan,2019-02-06 07:23:00-05:00,CDXS,positive
226837.0,"Codexis Reports Enzyme Supply Deal With KYORIN Pharma For Overactive Bladder Drug Sold In Japan, No Terms Disclosed",2019-02-06 07:05:00-05:00,CDXS,negative
226838.0,50 Biggest Movers From Yesterday,2019-02-06 05:03:00-05:00,CDXS,neutral
226839.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-02-05 12:35:00-05:00,CDXS,neutral
226840.0,32 Stocks Moving In Tuesday's Pre-Market Session,2019-02-05 07:53:00-05:00,CDXS,neutral
226841.0,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",2019-02-05 07:47:00-05:00,CDXS,positive
226842.0,UPDATE: Financial Terms Of Codexis/Merck Deal Were Not Disclosed,2019-02-04 16:21:00-05:00,CDXS,neutral
226843.0,Codexis Reports Secured Multi-Year Technology Upgrade Package For CodeEvolver Protein Engineering Platform License With Merck,2019-02-04 16:21:00-05:00,CDXS,positive
226844.0,48 Biggest Movers From Yesterday,2019-01-18 05:06:00-05:00,CDXS,neutral
226845.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-01-17 12:45:00-05:00,CDXS,neutral
226846.0,First Analysis Upgrades Codexis to Outperform,2019-01-17 08:15:00-05:00,CDXS,neutral
226847.0,UPDATE: Codexis Says FDA Concluded Co. Can Proceed With Clinical Trial Protocol CDX6114-003,2019-01-10 16:10:00-05:00,CDXS,neutral
226848.0,Codexis 8-K Shows Co. Received Notice From FDA On Completion Of Safety Review For Co.'s Investigation New Drug Application For CDX-6114,2019-01-10 16:09:00-05:00,CDXS,positive
226849.0,"Codexis Filing Shows Registration For Mixed Securities Offering, No Terms Disclosed",2018-12-06 16:56:00-05:00,CDXS,neutral
226850.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,CDXS,neutral
226851.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",2018-11-30 10:25:00-05:00,CDXS,neutral
226852.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 28, 2018",2018-11-29 10:49:00-05:00,CDXS,neutral
226853.0,"Codexis Q3 EPS $0.00 Beats $(0.07) Estimate, Sales $16.946M Beat $14.84M Estimate",2018-11-08 16:48:00-05:00,CDXS,neutral
226854.0,Codexis' Phase 1a Trial of CDX-6114 Met All Endpoints,2018-11-08 09:06:00-05:00,CDXS,neutral
226855.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,CDXS,neutral
226856.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,CDXS,neutral
226857.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,CDXS,neutral
226858.0,"Stocks Which Set New 52-Week High Friday, September 7th",2018-09-10 16:36:00-04:00,CDXS,neutral
226859.0,"Stocks That Made New 52-Week Highs Yesterday, September 6th",2018-09-07 16:47:00-04:00,CDXS,neutral
226860.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,CDXS,neutral
226861.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,CDXS,neutral
226862.0,Codexis Sees FY18 Sales $60M-$63M vs $62.11M Est.,2018-08-08 17:04:00-04:00,CDXS,neutral
226863.0,"Codexis Q2 Adj. EPS $(0.02) Beats $(0.12) Estimate, Sales $13.5M Beat $11.6M Estimate",2018-08-08 17:03:00-04:00,CDXS,neutral
226864.0,"Benzinga's Top Upgrades, Downgrades For June 19, 2018",2018-06-19 09:17:00-04:00,CDXS,positive
226865.0,"Cowen & Co. Initiates Coverage On Codexis with Outperform Rating, Announces $18 Price Target",2018-06-19 06:25:00-04:00,CDXS,neutral
226866.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,CDXS,neutral
226867.0,Volume Spike In Codexis Being Attributed By Traders To Unconfirmed Chatroom Chatter Of A Positive Newsletter Mention,2018-05-21 11:44:00-04:00,CDXS,positive
226868.0,Codexis Sees FY2018 Sales $60.0M-63.0M vs $62.95M Est,2018-05-10 17:04:00-04:00,CDXS,neutral
226869.0,"Codexis Q1 EPS $(0.05) Beats $(0.11) Estimate, Sales $14M Beat $12.1M Estimate",2018-05-10 17:04:00-04:00,CDXS,neutral
226870.0,"Porton Pharma Solutions, Codexis Launch Global Partnership To Deploy Codexis Biocatalyst Tech Within Porton's Global Custom Intermediate And Active Pharmaceutical Ingredients",2018-04-23 06:01:00-04:00,CDXS,positive
226871.0,Codexis Shares Down 4.7% After Co. Thursday Priced 3.75M Share Common Stock Offering At a Discount,2018-04-06 12:29:00-04:00,CDXS,positive
226872.0,24 Stocks Moving In Friday's Mid-Day Session,2018-04-06 12:26:00-04:00,CDXS,neutral
226873.0,Codexis Late Thursday Priced 3.75M Share Offering At $9.25/Share,2018-04-06 08:27:00-04:00,CDXS,positive
226874.0,18 Stocks Moving In Friday's Pre-Market Session,2018-04-06 08:19:00-04:00,CDXS,neutral
226875.0,"A Peek Into The Markets: US Stock Futures Tumble, Jobs Data In Focus",2018-04-06 07:51:00-04:00,CDXS,neutral
226876.0,"6 Stocks To Watch For April 6, 2018",2018-04-06 04:20:00-04:00,CDXS,neutral
226877.0,5 Stocks Moving In Thursday's After-Hours Session,2018-04-05 17:23:00-04:00,CDXS,neutral
226878.0,Codexis Shares Down 5.1% In After-Hours Trading Following Co.'s Announcement Of Common Stock Offering,2018-04-05 16:57:00-04:00,CDXS,positive
226879.0,"Codexis Announces Proposed Public Offering of Common Stock, No Size Disclosed",2018-04-05 16:02:00-04:00,CDXS,negative
226880.0,Mid-Day Market Update: Dow Rises Over 200 Points; Invuity Shares Plummet,2018-03-15 12:25:00-04:00,CDXS,positive
226881.0,24 Stocks Moving In Tuesday's Pre-Market Session,2018-03-13 08:00:00-04:00,CDXS,neutral
226882.0,46 Biggest Movers From Yesterday,2018-03-13 05:38:00-04:00,CDXS,neutral
226883.0,Codexis Sees FY18 Sales $60M-$63M vs $68.6M Est.,2018-03-08 16:39:00-05:00,CDXS,neutral
226884.0,"Codexis Reports Q4 Adj. EPS $0.06 vs $0.05 Est., Sales $21.7M vs $23M Est.",2018-03-08 16:39:00-05:00,CDXS,neutral
226885.0,Codexis Q4 Earnings Preview,2018-03-08 09:32:00-05:00,CDXS,neutral
226886.0,Codexis 13G Filing From Telemark Asset Mgmt. Shows Raised Stake To 6.72%,2017-11-20 17:33:00-05:00,CDXS,positive
226887.0,Codexis Sees FY17 Sales $50-$53M vs $51.2M Est.,2017-11-09 16:15:00-05:00,CDXS,neutral
226888.0,"Codexis Reports Q3 EPS $(0.17) vs $(0.17) Est., Sales $10M vs $10M Est.",2017-11-09 16:15:00-05:00,CDXS,neutral
226889.0,UPDATE: Codexis Says Nestle Health Science To Make Upfront Payment Of $14M,2017-10-12 08:04:00-04:00,CDXS,neutral
226890.0,"Codexis, Nestle Health Science Report Parternship Related To Protein Engineering Platform",2017-10-12 08:04:00-04:00,CDXS,neutral
226891.0,Seeing Notable Block Trade In Codexis; 1.1M Shares At $5.775,2017-09-14 15:55:00-04:00,CDXS,negative
226892.0,"Codexis Reports Q2 Adj. EPS $(0.09) vs $(0.13) Est., Sales $10.3M vs $10.1M Est.",2017-08-09 16:20:00-04:00,CDXS,neutral
226893.0,Court Declares EnzymeWorks' Infringement Of 10 Codexis Patents,2017-08-08 17:51:00-04:00,CDXS,negative
226894.0,Secondary Offering Lockups Expiring Today Include Catalyst Biosciences and Codexis,2017-07-06 09:08:00-04:00,CDXS,neutral
226895.0,Mid-Day Market Update: Crude Oil Down 2%; Synergy Pharma Shares Spike Higher,2017-06-02 12:15:00-04:00,CDXS,negative
226896.0,"Benzinga's Top Upgrades, Downgrades For May 31, 2017",2017-05-31 09:21:00-04:00,CDXS,positive
226897.0,"Jefferies Initiates Coverage On Codexis with Buy Rating, Announces $8.00 Price Target",2017-05-31 06:38:00-04:00,CDXS,neutral
226898.0,Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss,2017-05-19 14:30:00-04:00,CDXS,negative
226899.0,"Codexis Reports Q1 Adj. EPS $(0.13) vs $(0.16) Est., Sales $8M vs $9.2M Est.",2017-05-09 17:29:00-04:00,CDXS,neutral
226900.0,18 Biggest Mid-Day Losers For Friday,2017-04-07 12:34:00-04:00,CDXS,negative
226901.0,Codexis Prices 5.5M Shares at $4/Share,2017-04-07 09:19:00-04:00,CDXS,positive
226902.0,"Codexis Reports Offering of Common Shares, No Amount Disclosed",2017-04-06 16:01:00-04:00,CDXS,neutral
226903.0,Codexis Reports Signing of Multi-Year Deal with Tate & Lyle,2017-03-31 07:05:00-04:00,CDXS,neutral
226904.0,"Codexis Reports Q4 Adj. EPS $(0.07) vs $0.02 in Same Qtr. Last Year, Sales $10M vs $11.6M in Same Qtr. Last Year",2017-03-09 16:09:00-05:00,CDXS,neutral
226905.0,Biomedical Sciences Investment Fund Pte Ltd Reports 7.17% Stake in Codexis in 13G,2017-02-13 06:24:00-05:00,CDXS,neutral
226906.0,First Analysis Downgrades Codexis To Equal-Weight,2017-01-26 08:37:00-05:00,CDXS,neutral
226907.0,Ladenburg Thalmann Upgrades Codexis to Buy,2017-01-04 07:46:00-05:00,CDXS,neutral
226908.0,"Codexis Reports Q3 EPS $0.09 vs. Est. $(0.14), Rev. $14.87M vs. Est. $7.41M",2016-11-08 16:10:00-05:00,CDXS,neutral
226909.0,"After-Hours Gainers Aug. 9, 2016: CLNE Up 18.5%, OCN 12%, VSAR 11.5%, YELP 10.3%, DXPE 8.9%, BBSI 8.6%, SPHS 7.4%, DHT 7.7%, EKSO 7.6%, CDXS 7.5%, YRD 7.4%, VRNS 7.3%",2016-08-09 19:15:00-04:00,CDXS,neutral
226910.0,Codexis Sees FY16 Rev. $46-$49M vs. Est. $47M,2016-08-09 17:18:00-04:00,CDXS,neutral
226911.0,"Codexis Reports Q2 EPS $0.12 vs. Est. $0.03, Rev. $16M vs. Est. $15.1M",2016-08-09 17:17:00-04:00,CDXS,neutral
226912.0,Codexis Affirms FY16 Sales $46M-$49M vs $47.6M Est.,2016-05-09 17:14:00-04:00,CDXS,neutral
226913.0,"Codexis Reports Q1 Adj. EPS $(0.11) vs $(0.15) Est., Sales $8M vs $7.5M Est.",2016-05-09 17:14:00-04:00,CDXS,neutral
226914.0,Codexis Announces Completion CodeEvolver Technology Transfer to GSK; Earns $7.5M Milestone Payment,2016-05-02 07:04:00-04:00,CDXS,neutral
226915.0,Mid-Morning Market Update: Markets Open Lower; General Motors Beats Q1 Views,2016-04-21 10:07:00-04:00,CDXS,negative
226916.0,Codexis Sees FY16 Sales $46M-$49M vs $47.6M Est.,2016-03-03 16:26:00-05:00,CDXS,neutral
226917.0,"Codexis Reports Q4 EPS $(0.05) vs $(0.04) Est., Sales $11.6M vs $11.63M Est.",2016-03-03 16:26:00-05:00,CDXS,neutral
226918.0,"Codexis Reports Filing of Suit Against EnzymeWorks, CEO Tao for Patent Infringement, Misappropriation of Trade Secrets",2016-02-22 08:22:00-05:00,CDXS,negative
226919.0,The Biggest Movers In Friday's After-Hours Session,2016-02-12 17:01:00-05:00,CDXS,neutral
226920.0,Why This Codexis Analyst Is Confident Stock Is Worth $6,2016-01-06 12:51:00-05:00,CDXS,positive
226921.0,Benzinga's Top Initiations,2016-01-06 10:05:00-05:00,CDXS,positive
226922.0,"H.C. Wainwright Initiates Coverage on Codexis at Buy, Announces $6.00 PT",2016-01-06 07:06:00-05:00,CDXS,neutral
226923.0,"Codexis +7.1% Premarket @$4.50;, Co Announces Agreement Extension With Merck",2015-12-18 07:54:00-05:00,CDXS,positive
226924.0,"Codexis Reports Q3 EPS $0.19 vs. Est. $(0.11), Rev. $17.4M vs. Est. $8.32M",2015-11-04 18:00:00-05:00,CDXS,neutral
226925.0,Codexis Announces $5M Milestone Payment From Merck,2015-10-15 07:05:00-04:00,CDXS,neutral
226926.0,Codexis Earns $6.5M Technology Transfer Milestone Payment From GSK,2015-10-08 07:03:00-04:00,CDXS,neutral
226927.0,Mid-Morning Market Update: Markets Open Lower; Wal-Mart Lowers Full-Year Forecast,2015-08-18 10:32:00-04:00,CDXS,negative
226928.0,Codexis Raises FY15 Sales Guidance from $39M-$42M to $41M-$44M vs $41M Est.,2015-08-11 16:07:00-04:00,CDXS,neutral
226929.0,"Codeix Reports Q2 Sales $6M vs $7.34M Est., Adj. Loss of $0.07/Share vs Loss of $0.12/Share Est.",2015-08-11 16:07:00-04:00,CDXS,negative
226930.0,Codexis Partners With Leading Biopharmaceutical Company to Apply CodeEvolver Protein Engineering in Therapeutics Development Program,2015-08-11 07:03:00-04:00,CDXS,neutral
226931.0,"Wednesday's After-Hours Movers Led By Keurig Green Mountain, Tesla, Herbalife, Codexis, Fitbit And More",2015-08-05 16:55:00-04:00,CDXS,neutral
226932.0,Morning Market Gainers,2015-08-04 09:45:00-04:00,CDXS,neutral
226933.0,"Codexis Reports CodeEvolver Technology Transfer, License Deal with Merck; Will Receive Up to $5M Upfront Payment, Eligibile for Up to $18M in Milestones",2015-08-03 16:34:00-04:00,CDXS,neutral
226934.0,"Codexis Reports Q1 Adj Loss $0.07 Vs Est Loss $0.12, Sales $6.8M Vs Est $7.98M",2015-05-07 16:37:00-04:00,CDXS,negative
226935.0,Vivo Ventures VII Reports 14.04% Passive Stake In Codexis,2015-03-23 15:51:00-04:00,CDXS,positive
226936.0,Ladenburg Thalmann Downgrades Codexis to Neutral,2015-03-04 07:51:00-05:00,CDXS,neutral
226937.0,"Codexis Reports Q4 EPS $0.07 vs. $0.01, Rev. $14.2M vs. $13.32M",2015-03-03 16:08:00-05:00,CDXS,neutral
226938.0,Stocks Hitting 52-Week Highs,2015-02-02 10:17:00-05:00,CDXS,neutral
226939.0,"Codexis Director Yang Buys 20,000 Shares @$2.35/Share -Form 4",2014-11-20 09:05:00-05:00,CDXS,positive
226940.0,"Codexis, Inc. Reports Q3 EPS of $(0.05) vs $(0.06) Est",2014-11-04 16:18:00-05:00,CDXS,neutral
226941.0,Codexis Shares Spike Higher on Mention as Ebola Play,2014-10-13 15:41:00-04:00,CDXS,positive
226942.0,Codexis Announces Gordon Sangster CFO,2014-07-28 16:02:00-04:00,CDXS,neutral
226943.0,Morning Market Movers ,2014-07-15 09:46:00-04:00,CDXS,neutral
226944.0,Shares of Codexis Now Trading Up ~90% to $2.75,2014-07-14 16:53:00-04:00,CDXS,positive
226945.0,"Codexis Shares Now Open for Trade, Not Seeing Any New Last Trade Prices",2014-07-14 16:30:00-04:00,CDXS,positive
226946.0,Shares of Codexis to Resume Trade at 4:30 p.m. EDT,2014-07-14 16:12:00-04:00,CDXS,positive
226947.0,Codexis Announces Technology Collaboration And License Agreement With GSK; Codexis To Receive $25M Over Next 2 Yrs,2014-07-14 16:02:00-04:00,CDXS,positive
226948.0,Codexis Shares Halted News Pending,2014-07-14 16:00:00-04:00,CDXS,positive
226949.0,"Codexis, Inc. Reports Q1 EPS of $(0.17) vs $(0.10) Est; Revenue of $7.10M vs $10.0M Est",2014-05-07 16:15:00-04:00,CDXS,neutral
226950.0,UPDATE: Codexis Sells Hungarian Operations to IntreXon,2014-03-13 16:31:00-04:00,CDXS,neutral
226951.0,"Codexis, Inc. Sees FY2014 Sales $33.0M-35.0M vs $35.50M Est",2014-03-11 16:16:00-04:00,CDXS,neutral
226952.0,"Codexis, Inc. Reports Q4 EPS of $(0.26) vs $(0.21) Est; Revenue of $9.81M vs $10.0M Est",2014-03-11 16:15:00-04:00,CDXS,neutral
226953.0,Benzinga Weekly Preview: Ukraine Tension Likely To Drive Markets,2014-03-07 16:11:00-05:00,CDXS,negative
226954.0,"Codexis, Inc. Lowers FY2013 Sales Guidance from $35.0M-40.0M to $30.0M-32.0M vs $35.80M Est",2013-11-12 16:03:00-05:00,CDXS,negative
226955.0,"Codexis, Inc. Reports Q3 EPS of $(0.24) vs $(0.31) Est; Revenue of $9.26M vs $8.50M Est",2013-11-12 16:02:00-05:00,CDXS,neutral
226956.0,"Codexis, Inc. Reports Q2 EPS of $(0.33) vs $(0.28) Est; Revenue of $7.0M vs $9.0M Est",2013-08-09 16:15:00-04:00,CDXS,neutral
226957.0,Codexis Reschedules Second Quarter 2013 Financial Results ,2013-08-05 16:08:00-04:00,CDXS,neutral
226958.0,Codexis Receives Notice Alleging Breach of Dyadic License Agreement ,2013-08-05 16:03:00-04:00,CDXS,positive
226959.0,Afternoon Market Gainers ,2013-06-14 12:36:00-04:00,CDXS,neutral
226960.0,"Codexis, Inc. Reports Q1 EPS of $(0.25) vs $(0.35) Est; Revenue of $11.50M vs $7.63M Est",2013-05-07 16:14:00-04:00,CDXS,neutral
226961.0,Codexis Delays 10-K Filing,2013-03-18 17:13:00-04:00,CDXS,neutral
226962.0,Codexis Launches CodeXyme Cellulase Enzymes,2013-03-12 05:46:00-04:00,CDXS,neutral
226963.0,"Codexis, Inc. Reports Q4 EPS of $(0.41) vs $(0.36) Est; Revenue of $7.90M",2013-02-27 16:02:00-05:00,CDXS,neutral
226964.0,Codexis Reports Q3 EPS $-0.06 vs $-0.18 Est; Revenues $26.3M vs $24.36M Est,2012-11-07 16:17:00-05:00,CDXS,neutral
226965.0,Codexis Reports Q3 EPS $-0.06 vs $-0.18 Est; Revenues $26.3M vs $24.36M Est,2012-11-07 16:16:00-05:00,CDXS,neutral
226966.0,UPDATE: Piper Jaffray Upgrades Codexis to Neutral Post Shell Agreement Termination  ,2012-09-05 12:46:00-04:00,CDXS,positive
226967.0,Benzinga's Top Upgrades,2012-09-05 07:19:00-04:00,CDXS,positive
226968.0,"Piper Jaffray Upgrades Codexis from Underweight to Neutral, Maintains PT at $2",2012-09-05 05:46:00-04:00,CDXS,neutral
226969.0,Shell Grants Codexis Rights to Commercialize Cellulase Enzymes for Biofuels,2012-09-04 07:46:00-04:00,CDXS,positive
226970.0,Codexis Appoints David O'Toole as Chief Financial Officer ,2012-09-04 07:14:00-04:00,CDXS,neutral
226971.0,"UPDATE: Piper Jaffray Reiterates Underweight Rating, Lowers PT on Codexis",2012-08-10 11:42:00-04:00,CDXS,negative
226972.0,"Piper Jaffray Maintains Codexis at Underweight, Lowers PT from $3 to $2",2012-08-10 06:54:00-04:00,CDXS,negative
226973.0,"Credit Suisse Downgrades Codexis from Outperform to Neutral, Lowers PT from $10 to $4",2012-08-10 06:40:00-04:00,CDXS,positive
226974.0,Codexis Reports Q2 EPS $-0.15 vs $-0.19 Est; Revenues $22.9M vs $29.84M Est,2012-08-09 16:05:00-04:00,CDXS,neutral
226975.0,Codexis Advances Fuels Discussions with Shell   ,2012-07-16 16:05:00-04:00,CDXS,neutral
226976.0,Codexis Announces Interim CFO Departure   ,2012-06-13 16:29:00-04:00,CDXS,neutral
226977.0,Codexis Announces Inducement Option Award and Restricted Stock Award to CEO John J. Nicols   ,2012-06-13 16:23:00-04:00,CDXS,positive
226978.0,Codexis Appoints John J. Nicols as President and Chief Executive Officer   ,2012-06-04 08:04:00-04:00,CDXS,neutral
226979.0,Codexis Announces Three-Year Extension of Collaboration Agreement with Merck,2012-05-22 09:01:00-04:00,CDXS,positive
226980.0,USPTO Grants Codexis Patent for Enzymes Used in Hep-C Therapeutics   ,2012-05-15 16:07:00-04:00,CDXS,positive
226981.0,"UPDATE: Piper Jaffray Reiterates Underweight Rating, Lowers PT for Codexis",2012-05-11 10:49:00-04:00,CDXS,negative
226982.0,"Piper Jaffray Maintains Codexis at Underweight, Lowers PT from $3.5 to $3",2012-05-11 07:07:00-04:00,CDXS,negative
226983.0,"Benzinga's Microcap Movers for Wednesday April 25, 2012",2012-04-25 16:30:00-04:00,CDXS,neutral
226984.0,Codexis Announces FDA Approves Use of Codexis Enzymes in Merck Manufacturing Process  ,2012-04-24 16:06:00-04:00,CDXS,positive
226985.0,Merck,2012-04-03 18:47:00-04:00,CDXS,neutral
226986.0,Codexis and Merck Develop Prototype Enzyme-Based Method for Production of Boceprevir  ,2012-04-03 16:06:00-04:00,CDXS,neutral
226987.0,Codexis Awarded Biofuels Enzyme Patent   ,2012-03-27 16:10:00-04:00,CDXS,positive
226988.0,UPDATE: Piper Jaffray Downgrades Codexis; Lowers PT,2012-02-21 09:11:00-05:00,CDXS,negative
226989.0,Benzinga's Top Downgrades,2012-02-21 07:46:00-05:00,CDXS,positive
226990.0,"Financial Breakfast: Morning News Summary for February 21, 2012",2012-02-21 07:29:00-05:00,CDXS,neutral
226991.0,"Piper Jaffray Downgrades Codexis from Neutral to Underweight, Lowers PT from $5 to $3.5",2012-02-21 06:34:00-05:00,CDXS,negative
226992.0,Codexis Appoints Interim Chief Executive Officer,2012-02-17 16:05:00-05:00,CDXS,neutral
226993.0,Codexis Reports Q4 EPS $(0.15) May Not Compare vs $(0.11) Est; Revenues $33.5M vs $32.11M Est				 ,2012-02-07 16:17:00-05:00,CDXS,neutral
226994.0,Codexis Announces CFO Departure ,2012-01-24 16:05:00-05:00,CDXS,neutral
226995.0,Codexis Names Wes Bolsen VP and Chief Marketing Officer ,2011-12-05 08:06:00-05:00,CDXS,neutral
226996.0,Investor Ideas: Wednesday's NASDAQ Winners,2011-11-03 11:46:00-04:00,CDXS,positive
226997.0,Codexis Sees 2011 Revenue $120M vs $122M Est,2011-11-01 16:30:00-04:00,CDXS,neutral
226998.0,Codexis Inc Reports Q3 EPS $(0.08) vs $(0.08) Est; Revenues $33.3M vs $31.65M Est			,2011-11-01 16:30:00-04:00,CDXS,neutral
226999.0,Department of Energy Announces $41 Million Investment for Carbon Capture Development,2011-08-25 13:50:00-04:00,CDXS,positive
227000.0,Codexis Reports Q2 EPS $(0.14) vs $(0.09) Est; Revenues $26.1M vs $29.83M Est,2011-07-28 16:21:00-04:00,CDXS,neutral
227001.0,Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market ,2011-07-28 16:08:00-04:00,CDXS,neutral
227002.0,Codexis Announces First Cellulase Enzyme Scale Up,2011-07-12 08:02:00-04:00,CDXS,neutral
227003.0,Top Percentage Gainers and Losers as of 2pm 6/20/11,2011-06-20 14:00:00-04:00,CDXS,negative
227004.0,UPDATE: Piper Jaffray Downgrades Codexis to Neutral,2011-06-20 08:44:00-04:00,CDXS,neutral
227005.0,"Piper Jaffray Downgrades Codexis To Neutral, Lowers PT To $11",2011-06-20 08:01:00-04:00,CDXS,negative
227006.0,Shell Transfers Its Codexis Shares to Raizen,2011-06-02 10:51:00-04:00,CDXS,positive
227007.0,Codexis CEO Alan Shaw Says Company Will Eventually Be Possible M&A Target -Bloomberg,2011-05-20 08:51:00-04:00,CDXS,neutral
227008.0,Codexis In Pact With Lactosan Gmbh & Co. Kg -Bloomberg,2011-05-19 16:12:00-04:00,CDXS,neutral
227009.0,Codexis Announces Expansion of Collaboration with Teva Pharmaceutical ,2011-05-16 08:06:00-04:00,CDXS,neutral
227010.0,Codexis Achieves Development Milestones With Teva ,2011-05-16 08:02:00-04:00,CDXS,neutral
227011.0,Piper Jaffray Reiterates OW Rating ON CDXS,2011-03-16 07:41:00-04:00,CDXS,neutral
227012.0,"Piper Jaffray Maintains Codexis Overweight, $14 PT (CDXS)",2011-02-04 09:08:00-05:00,CDXS,negative
227013.0,Codexis Reports Q4 EPS of $(0.01) vs. $(0.06),2011-02-03 16:22:00-05:00,CDXS,neutral
227014.0,"Piper Jaffray Maintains Overweight On Codexis, Inc.  (CDXS)",2011-01-14 07:30:00-05:00,CDXS,negative
227015.0,Piper Jaffray Raises PT On Codexis,2011-01-14 06:51:00-05:00,CDXS,neutral
227016.0,DSM and Codexis Sign Agreement ,2011-01-12 08:06:00-05:00,CDXS,positive
227017.0,Codexis Grows Revenue 35 Percent; EPS $(0.08),2010-10-28 16:29:00-04:00,CDXS,neutral
227018.0,Piper Jaffray Upgrades Codexis To Overweight (CDXS),2010-08-31 07:37:00-04:00,CDXS,negative
